PE20211979A1 - Anticuerpos anti-trem2 y metodos para utilizarlos - Google Patents
Anticuerpos anti-trem2 y metodos para utilizarlosInfo
- Publication number
- PE20211979A1 PE20211979A1 PE2021001367A PE2021001367A PE20211979A1 PE 20211979 A1 PE20211979 A1 PE 20211979A1 PE 2021001367 A PE2021001367 A PE 2021001367A PE 2021001367 A PE2021001367 A PE 2021001367A PE 20211979 A1 PE20211979 A1 PE 20211979A1
- Authority
- PE
- Peru
- Prior art keywords
- trem2
- disease
- expressed
- receptor
- myeloid cell
- Prior art date
Links
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 abstract 4
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 abstract 4
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000021320 Nasu-Hakola disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010057249 Phagocytosis Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000274 microglia Anatomy 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000008782 phagocytosis Effects 0.000 abstract 1
- 208000031334 polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly Diseases 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 102000027257 transmembrane receptors Human genes 0.000 abstract 1
- 108091008578 transmembrane receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 | |
| PCT/US2020/019093 WO2020172450A1 (en) | 2019-02-20 | 2020-02-20 | Anti-trem2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211979A1 true PE20211979A1 (es) | 2021-10-05 |
Family
ID=69844940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001367A PE20211979A1 (es) | 2019-02-20 | 2020-02-20 | Anticuerpos anti-trem2 y metodos para utilizarlos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12240902B2 (enExample) |
| EP (1) | EP3927743A1 (enExample) |
| JP (2) | JP7543290B2 (enExample) |
| KR (1) | KR20210135518A (enExample) |
| CN (1) | CN113614110B (enExample) |
| AR (1) | AR118144A1 (enExample) |
| AU (1) | AU2020226754A1 (enExample) |
| BR (1) | BR112021015656A2 (enExample) |
| CA (1) | CA3130086A1 (enExample) |
| CL (1) | CL2021002206A1 (enExample) |
| CO (1) | CO2021012230A2 (enExample) |
| EA (1) | EA202192294A1 (enExample) |
| EC (1) | ECSP21069105A (enExample) |
| IL (1) | IL285651A (enExample) |
| MA (1) | MA55025A (enExample) |
| MX (1) | MX2021009722A (enExample) |
| PE (1) | PE20211979A1 (enExample) |
| PH (1) | PH12021552002A1 (enExample) |
| SG (1) | SG11202108734VA (enExample) |
| TW (1) | TWI879756B (enExample) |
| WO (2) | WO2020172457A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| EA202191650A1 (ru) * | 2018-12-18 | 2021-10-22 | Бёрингер Ингельхайм Ио Канада Инк. | Flt3 агонистические антитела и их применения |
| EP3927743A1 (en) | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| KR20220131246A (ko) * | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
| EP4337317A1 (en) * | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Agonists of trem2 |
| KR20240149428A (ko) | 2022-02-23 | 2024-10-14 | 알렉터 엘엘씨 | 항-trem2 항체의 사용 방법 |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| EP4499693A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| EP4658684A1 (en) | 2023-01-30 | 2025-12-10 | ISAR Bioscience GmbH | Human anti-trem2 antibody for treating neurodegenerative disorders |
| WO2025032071A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| TW202515919A (zh) | 2023-09-01 | 2025-04-16 | 比利時商艾托斯比利時公司 | 抗ｔｒｅｍ２抗體及使用方法 |
| WO2025106361A1 (en) * | 2023-11-15 | 2025-05-22 | Merck Sharp & Dohme Llc | Human nectin-4 binders |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| WO2010079039A1 (en) | 2009-01-06 | 2010-07-15 | Nestec S.A. | Processing of macronutrients |
| KR101579771B1 (ko) | 2009-03-05 | 2015-12-28 | 애브비 인코포레이티드 | Ｉｌ-17 결합 단백질 |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| JPWO2012176779A1 (ja) * | 2011-06-20 | 2015-02-23 | 協和発酵キリン株式会社 | 抗ｅｒｂＢ３抗体 |
| EP2992013B1 (en) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US11261262B2 (en) | 2013-09-03 | 2022-03-01 | Novimmune Sa | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| US20170240631A1 (en) * | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| JP6996979B2 (ja) | 2015-03-31 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 三量体ｔｎｆファミリーリガンドを含む抗原結合分子 |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| WO2017147509A1 (en) | 2016-02-25 | 2017-08-31 | Marco Colonna | Compositions comprising trem2 and methods of use thereof |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| AU2017300040A1 (en) | 2016-07-22 | 2019-01-24 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | TREM2 cleavage modulators and uses thereof |
| CN118271442A (zh) | 2016-12-23 | 2024-07-02 | 蓝鳍生物医药公司 | 抗sez6l2抗体和抗体药物缀合物 |
| WO2018134815A2 (en) | 2017-01-17 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| FI3583120T3 (fi) | 2017-02-17 | 2023-01-13 | Muunneltuja transferriinireseptoria sitovia polypeptidejä | |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| JP2020530986A (ja) | 2017-07-27 | 2020-11-05 | ノバルティス アーゲー | シェダーゼ耐性ｔｒｅｍ２変異体 |
| DK3601358T5 (da) | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2019032955A1 (en) | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| WO2019079529A1 (en) | 2017-10-17 | 2019-04-25 | The Translational Genomics Research Institute | TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| KR102860409B1 (ko) | 2017-12-12 | 2025-09-16 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체 및 관련 방법 |
| WO2019140050A1 (en) | 2018-01-10 | 2019-07-18 | Denali Therapeutics Inc. | Transferrin receptor-binding polypeptides and uses thereof |
| JP7517997B2 (ja) | 2018-06-18 | 2024-07-17 | デナリ セラピューティクス インコーポレイテッド | プログラニュリンを含む融合タンパク質 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| SG11202101273VA (en) | 2018-08-16 | 2021-03-30 | Denali Therapeutics Inc | Engineered bispecific proteins |
| KR20210074279A (ko) | 2018-08-22 | 2021-06-21 | 데날리 테라퓨틱스 인크. | 항-her2 폴리펩타이드 및 이의 사용방법 |
| KR20210057113A (ko) | 2018-09-11 | 2021-05-20 | 워싱턴 유니버시티 | 항-trem-2 작용제 항체 |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| WO2020112889A2 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| MA54450A (fr) | 2018-12-10 | 2021-10-20 | Denali Therapeutics Inc | Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation |
| CA3122725A1 (en) | 2018-12-10 | 2020-06-18 | Mor Research Applications | Trem2 antibodies and uses thereof |
| CA3120875A1 (en) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
| EP3927743A1 (en) | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| MX2021011612A (es) | 2019-04-03 | 2021-12-10 | Denali Therapeutics Inc | Formulaciones de moleculas proteicas que comprenden iduronato 2-sulfatasa. |
| AU2020411480B2 (en) | 2019-12-23 | 2023-12-21 | Denali Therapeutics Inc. | Progranulin variants |
| KR20220131246A (ko) | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
| TWI890727B (zh) | 2020-01-13 | 2025-07-21 | 美商戴納立製藥公司 | 抗trem2 抗體及其使用方法 |
| EP4100419A4 (en) | 2020-02-07 | 2024-05-29 | Denali Therapeutics Inc. | METHODS OF TREATING HUNTER SYNDROME |
| CA3170338A1 (en) | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| MA71661A (fr) | 2020-10-14 | 2025-05-30 | Denali Therapeutics Inc. | Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées |
-
2020
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/en active Pending
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/en not_active Ceased
- 2020-02-20 CA CA3130086A patent/CA3130086A1/en active Pending
- 2020-02-20 AR ARP200100461A patent/AR118144A1/es unknown
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/pt unknown
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/es unknown
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/en not_active Ceased
- 2020-02-20 PH PH1/2021/552002A patent/PH12021552002A1/en unknown
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/es unknown
- 2020-02-20 CN CN202080015804.2A patent/CN113614110B/zh active Active
- 2020-02-20 EA EA202192294A patent/EA202192294A1/ru unknown
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
- 2020-02-20 MA MA055025A patent/MA55025A/fr unknown
- 2020-02-20 TW TW109105560A patent/TWI879756B/zh active
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/ko active Pending
- 2020-02-20 JP JP2021548668A patent/JP7543290B2/ja active Active
-
2021
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-16 US US17/402,986 patent/US12240902B2/en active Active
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en not_active Abandoned
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/es unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/es unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/es unknown
-
2024
- 2024-08-21 JP JP2024139367A patent/JP2024164116A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020226754A1 (en) | 2021-09-16 |
| US20220073609A1 (en) | 2022-03-10 |
| MX2021009722A (es) | 2021-09-14 |
| US20220119522A1 (en) | 2022-04-21 |
| AR118144A1 (es) | 2021-09-22 |
| TW202045543A (zh) | 2020-12-16 |
| TWI879756B (zh) | 2025-04-11 |
| CN113614110A (zh) | 2021-11-05 |
| MA55025A (fr) | 2021-12-29 |
| BR112021015656A2 (pt) | 2021-10-05 |
| CL2021002206A1 (es) | 2022-04-22 |
| WO2020172450A1 (en) | 2020-08-27 |
| WO2020172457A1 (en) | 2020-08-27 |
| CO2021012230A2 (es) | 2021-09-30 |
| ECSP21069105A (es) | 2021-11-18 |
| PH12021552002A1 (en) | 2022-09-19 |
| CN113614110B (zh) | 2025-03-25 |
| KR20210135518A (ko) | 2021-11-15 |
| US12240902B2 (en) | 2025-03-04 |
| CA3130086A1 (en) | 2020-08-27 |
| SG11202108734VA (en) | 2021-09-29 |
| JP2022520868A (ja) | 2022-04-01 |
| EP3927743A1 (en) | 2021-12-29 |
| EA202192294A1 (ru) | 2021-12-24 |
| JP7543290B2 (ja) | 2024-09-02 |
| JP2024164116A (ja) | 2024-11-26 |
| IL285651A (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211979A1 (es) | Anticuerpos anti-trem2 y metodos para utilizarlos | |
| CL2024002093A1 (es) | Anticuerpos anti-cd73. | |
| CL2022003769A1 (es) | Anticuerpos de unión a cd3 | |
| CO2019012998A2 (es) | Proteínas de unión a antígenos trem2 y usos de estas | |
| MX2017001531A (es) | Anticuerpos anti-trem2 y metodos de uso de los mismos. | |
| MX2022010229A (es) | Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8). | |
| PE20201341A1 (es) | Anticuerpos de union a gprc5d | |
| BRPI0711908B8 (pt) | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. | |
| AR066987A1 (es) | Anticuerpo monoclonal contra proteina beta-amiloide | |
| CL2021001162A1 (es) | Proteínas de fusión fc il-22 y métodos de uso. (divisional de solicitud 202001944) | |
| ZA202101325B (en) | Anti-ifnar1 antibodies for treating autoimmune disease | |
| AR079645A1 (es) | Anticuerpos antagonistas y sus fragmentos fab contra la proteina de las membranas plaquetarias humanas glicoproteina vi (gpvi) y sus usos | |
| BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
| MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| CO2020000260A2 (es) | Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide | |
| BR112017024852A2 (pt) | antagonistas de receptor nk-1/nk-3 duplo para o tratamento de doenças dependentes de hormônio sexual | |
| MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
| WO2020069050A3 (en) | Methods of treating neurodegenerative diseases | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| WO2021222181A3 (en) | Isoform-independent antibodies to lipoprotein(a) | |
| CL2021000902A1 (es) | Método para la fabricación de gemas sintéticas. | |
| EP3496716A4 (en) | COMPOUNDS FOR CHANGING THE CONCENTRATIONS OF BILE ACID FOR TREATING DIABETES AND CARDIOMETABOLIC DISEASES | |
| MX2025005500A (es) | Anticuerpos anti proteína plasmática a asociada al embarazo (papp-a) y métodos de uso de estos | |
| CO2022009711A2 (es) | Anticuerpo multiespecifico con especificidad de unión para il-13 e il-17 humanas | |
| CL2022002259A1 (es) | Anticuerpos anti-axl y composiciones |